T-Cell Lymphoma

Type: Keyphrase
Name: T-Cell Lymphoma
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Anti-cancer drug with active ingredient invented in Latvia approved in U.S.

At the beginning of July 2014, the United States Food and Drug Administration authorized the use of a new anti-cancer drug in medicine, the active ingredient of which was invented and synthesized in Latvia, the head of the Latvian Institute of Organic ... [Published The Baltic Course - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

9-aminonoscapine and its use in treating cancers, including drug-resistant cancers

9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog ... [Published Free Patents Online - Aug 26 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Cancer Therapy Advisor announces Publishers Alliance

ByG.P. Collins, D. Bruce, and T.A. EyreBiomarker-driven chemotherapeutics is becoming a critical part of the state-of-the-art treatment in early- and late-phase clinical trials involving patients with T-cell lymphoma. ... [Published Chemotherapy Advisor - Aug 22 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Antioch grad returning to normal after cancer fight

Antioch, TN (WSMV) -For the last year and a half, Antioch High School graduate Makayla Claussen has been fighting a rare illness.When Channel 4 last caught up with Claussen, she was getting ready for Christmas with her family and beginning to feel more ... [Published WSMV - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

New Therapies in T-cell Lymphoma

ABSTRACT: T-cell lymphomas represent 10–12% of all patients with non-Hodgkin lymphoma (NHL) in the Western world. When cutaneous T-cell lymphoma (CTCL) is excluded, peripheral T-cell lymphoma—not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma ... [Published Chemotherapy Advisor - Aug 21 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Pageant contestant not centered on beauty

By PENNY FLETCHERTeresa Hyatt of Hillsborough County has taken her volunteering with the American Cancer Society to a whole new level as she competes for the title of Mrs. International.Unlike most pageants where women get dressed up, wear bathing suits ... [Published Observer News - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

New pathology software improves cancer diagnosis

New software developed jointly by the MedUni Vienna and theVienna-based firm Tissuegnostics helps pathologists to identifycancerous tissue with greater accuracy and remove some of thevariability in current methods based on visual analysis of tissuesa ... [Published MTB Europe - Aug 15 2014]
Entities: Pathology, Cancer, Vienna
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

H.C. Wainwright & Co. Sees Significant Upside Ahead For Spectrum Pharmaceuticals

In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $15.00 price target on Spectrum Pharmaceuticals (NASDAQ: SPPI).In the report, H.C. Wainwright & Co. noted, “We are reiterating our BUY rating for Spectrum ... [Published Benzinga.com - Aug 08 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

New Technology Developed to Diagnose Cancer Cells

Image: Microscopic analysis system automatically acquires up to eight slides with immunohistochemically stained sections and performs quantitative analysis of staining intensities (Photo courtesy of TissueGnostics).Patient tumors can be analyzed for aberrant ... [Published Lab Medica - Aug 05 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

What is the Cause? Erythematous Rash

(MedPage Today) -- An elderly patient with known T-cell lymphoma and splenomegaly develops a well demarcated erythematous lesion on her upper arm. A biopsy of the lesion demonstrates a neutrophilic infiltrate. ... [Published MedPageToday.com - medical news plus CME for ph ... - Aug 04 2014]
First reported Jul 31 2014 - Updated Aug 01 2014 - 3 reports

Ziopharm and Solasia amend collaboration for darinaparsin

US drug developer Ziopharm Oncology (Nasdaq: ZIOP) and Japan’s Solasia Pharma, a developer of oncology pharmaceuticals in-licensed for commercialization in major markets throughout the world, announced today an amendment and restatement of their up to ... [Published Pharma Letter - Aug 01 2014]
First reported Jul 03 2014 - Updated Jul 04 2014 - 5 reports

BioAlliance's lymphoma drug Beleodaq gets accelerated approval from FDA

France-based BioAlliance Pharma has received topotarget accelerated approval from the US Food and Drug Administration (FDA) for Beleodaq to treat patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). ... [Published PBR - News - Jul 04 2014]

Quotes

"My brother wasn't a match, so they went to bone marrow registry and they found a lady from Germany who was a match" Claussen said. "She saved my life."
"The lymphatic system produces B-lymphocytes and T-lymphocytes, disease-fighting white blood cells that travel through the blood in a fluid called lymph,” says Mona Rosenberg, D V M , a board-certified veterinary oncologist and founder of Veterinary Cancer Group, which has four locations in Southern California. "Lymphoma occurs when lymphocytes grow uncontrollably, forming tumors in the lymph nodes that can spread to the organs, tissues, and bone marrow.”"
"Solasia stands to benefit greatly from the acquisition of exclusive global development and commercialization rights to darinaparsin from Ziopharm" said Yoshihiro Arai, president and representative director of Solasia Pharma,” noting that it plans to start pivotal clinical trials in Asia early in...
...initial clinical studies with darinaparsin for PTCL have been extremely promising, which inspired the firm to expand its deal with Ziopharm. "We presently plan to start pivotal clinical trials in Asia early in 2015" he added

More Content

All (56) | News (48) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Onxeo Strengthens Beleodaq® Patent Protection i... [Published Market Pulse Navigator - Aug 28 2014]
Spectrum Pharmaceuticals: A Long-Term Bet [Published Seeking Alpha - Aug 28 2014]
Shift of HIV Tropism in Stem-Cell Transplantati... [Published New England Journal of Medicine - Aug 28 2014]
Anti-cancer drug with active ingredient invente... [Published The Baltic Course - Aug 26 2014]
9-aminonoscapine and its use in treating cancer... [Published Free Patents Online - Aug 26 2014]
Cancer Therapy Advisor announces Publishers All... [Published Chemotherapy Advisor - Aug 22 2014]
Antioch grad returning to normal after cancer f... [Published WSMV - Aug 21 2014]
New Therapies in T-cell Lymphoma [Published Chemotherapy Advisor - Aug 21 2014]
Pageant contestant not centered on beauty [Published Observer News - Aug 15 2014]
New pathology software improves cancer diagnosis [Published MTB Europe - Aug 15 2014]
Leukemia & Lymphoma Society seeks contributors ... [Published Mississippi Press - Aug 13 2014]
Canine Cancer: Lymphoma [Published DogChannel.com - Aug 13 2014]
Aratana Therapeutics' (PETX) CEO Steven St. Pet... [Published Seeking Alpha - Aug 12 2014]
Spectrum Pharmaceuticals (SPPI) Posts Strong Ea... [Published Zacks.com - Aug 12 2014]
Diagnosis and Management of Adult Celiac Disease [Published General Medicine eJournal - Aug 11 2014]
Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shr... [Published Seeking Alpha - Aug 10 2014]
Heart of a fighter: 33-year-old battles heart d... [Published Wise County Messenger - Aug 09 2014]
Karyopharm Therapeutics' (KPTI) CEO Michael Kau... [Published Seeking Alpha - Aug 08 2014]
H.C. Wainwright & Co. Sees Significant Upside A... [Published Benzinga.com - Aug 08 2014]
Solasia Acquires License For ZIOPHARM’s Darinap... [Published Asian Scientist - Aug 08 2014]
New Technology Developed to Diagnose Cancer Cells [Published Lab Medica - Aug 05 2014]
Seattle Genetics Up on Narrower-than-Expected Q... [Published Zacks.com - Aug 04 2014]
What is the Cause? Erythematous Rash [Published MedPageToday.com - medical news plus CME for ph ... - Aug 04 2014]
Seattle Genetics' (SGEN) CEO Clay Siegall on Q2... [Published Seeking Alpha - Aug 03 2014]
Ziopharm and Solasia amend collaboration for da... [Published Pharma Letter - Aug 01 2014]
Solasia Nabs Global Rights to Ziopharm's Zinapar [Published Genetic Engineering News - Aug 01 2014]
Teen won't let cancer slow him down [Published Queensland Times - Aug 01 2014]
ZIOPHARM Oncology and Solasia Pharma Announce G... [Published GlobeNewswire - Jul 31 2014]
Fully Human Antagonistic Antibodies against CCR... [Published Plosone.org - Jul 31 2014]
New products for pharmacists 08-10-2014 [Published Drugtopics.com - Jul 31 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
What is the Cause? Erythematous Rash [Published MedPageToday.com - medical news plus CME for ph ... - Aug 04 2014]
(MedPage Today) -- An elderly patient with known T-cell lymphoma and splenomegaly develops a well demarcated erythematous lesion on her upper arm. A biopsy of the lesion demonstrates a neutrophilic infiltrate. ...
Weekly Roundup 7.4.14 [Published Eye on FDA - Jul 04 2014]
Happy Independence Day for America.  This week also so Canada Day.  So while a week where work productivity may have dipped, enjoyment factors probably drove up – at least in North America.  The season is marked by hot, humid days and stormy nights, ...
BioAlliance's lymphoma drug Beleodaq gets accel... [Published PBR - News - Jul 04 2014]
France-based BioAlliance Pharma has received topotarget accelerated approval from the US Food and Drug Administration (FDA) for Beleodaq to treat patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). ...
BioAlliance Pharma: FDA approval of Beleodaq™ (... [Published Business Wire Health News - Jul 03 2014]
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Topotarget ...
Beleodaq Approved for Aggressive non-Hodgkin Ly... [Published Yahoo! Health News - Jul 03 2014]
THURSDAY, July 3, 2014 (HealthDay News) -- Beleodaq (belinostat) has been approved by the U.S. Food and Drug Administration to treat peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of non-Hodgkin lymphoma (cancer of the lymph nodes).... ...
1 2

Press Releases

sort by: Date | Relevance
Topotarget confirms receipt of acceptance-to-fi... [Published GlobeNewswire: Advertising News - Mar 26 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.